Neurocritical Care News

NeuroPace Inc. announced that the first patient with Lennox-Gastaut Syndrome was treated in its investigational device exemption feasibility study, which will evaluate the company’s neuromodulation technology.

Clinical-stage biopharmaceutical company Clene Inc. announced proof-of-concept evidence of potential neuroprotective effects of CNM-Au8, an oral therapeutic for patients with stable relapsing-remitting MS.

Biotechnology company Cajal Neuroscience announced its launch with $96 million Series A financing with plans to combine human genetics, functional genomics and advanced microscopy to expand drug discovery for neurodegenerative diseases.

Preclinical biotech company Eikonoklastes Therapeutics and gene therapy manufacturer Forge Biologics announced a partnership that will advance Eikonoklastes’ ET-101 gene therapy into clinical trials for patients with ALS.

The Feinstein Institutes for Medical Research has been awarded a $3.6 million grant, to be distributed over 5 years, from the New York State Department of Health for the study of spinal cord simulation and novel brain implant technology.

Klotho protein levels in cerebrospinal fluid and plasma were associated with clinical stages of Alzheimer’s disease, cognitive decline, and amyloid and tau burden, independent of KL-VS heterozygosity status, according to research.

Published results showed military cadets and athletes who reported a history of undiagnosed concussions had greater baseline symptom severity scores and psychological distress, as well as worse neurocognitive outcomes.

Lysogene has announced topline results from its phase 2/3 study evaluating LYS-SAF302, an investigational gene therapy for the treatment of mucopolysaccharidosis type IIIA, or Sanfilippo syndrome.

Researchers at Emory University are developing a visual tool to view how conditions such as Alzheimer's disease and autism spectrum disorder affect the brain in real-time, the university announced in a press release.

A practical risk score tool has been developed to help people identify their potential risk for dementia, researchers reported in JAMA Network Open.